2022 World Conference on Lung Cancer (ePosters)-EP08.02-004. Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

EP08.02-004. Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

Back to course

Pdf Summary

Aumolertinib, a novel third-generation EGFR-TKI, has shown promise in the treatment of EGFR-mutant NSCLC patients with brain metastases. The ongoing ARTISTRY study is evaluating the efficacy and safety of aumolertinib in this patient population. The primary efficacy and safety data of the brain parenchyma metastases cohort from the ARTISTRY study was presented.<br /><br />The study included 14 patients with baseline brain scans, 12 of whom had measurable and/or non-measurable CNS lesions. The patients had a median age of 62.5 years and were predominantly female non-smokers with adenocarcinoma. The overall response rates were evaluated in two different dosages of aumolertinib (110mg and 165mg). In the 110mg dosage group, the intracranial objective response rate (iORR) was 66.7%, and the intracranial disease control rate (iDCR) was 100%. In the 165mg dosage group, there were no observed responses. The safety profile of aumolertinib was manageable, with no grade 3 adverse events reported.<br /><br />A case study was presented of a 51-year-old female patient with stage IVB lung adenocarcinoma and brain metastases. The patient showed partial response to aumolertinib treatment.<br /><br />In conclusion, aumolertinib demonstrated promising antitumor activity in EGFR-mutant NSCLC patients with brain metastases, with a manageable safety profile. Dose escalation to 165mg provided preliminary benefit in patients experiencing intracranial progression. The study will continue enrollment, and further analyses are needed to assess long-term outcomes. The study was sponsored by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Asset Subtitle

Huijuan Wang

Meta Tag

Speaker Huijuan Wang

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Aumolertinib

EGFR-TKI

NSCLC

brain metastases

ARTISTRY study

efficacy

safety

intracranial objective response rate

dose escalation

Jiangsu Hansoh Pharmaceutical Group Co. Ltd.